Articles in refereed journals
Warren AM, Grossmann M, Hoermann R, Lin R, Zajac JD, Russell N (2025): Tolvaptan vs fluid restriction in moderate-profound hyponatremia: An open-label randomized clinical trial. J Clin Endocrinol Metab (online ahead of print). DOI: 10.1210/clinem/dgaf428
Dandash O, …, Russell N,..., Kanaan RA (2024). The effect of estradiol add-back: a longitudinal MRI study in prostate cancer patients. Endocrine Connections (online ahead of print). DOI: 10.1530/EC-23-0409
Warren AM, Grossmann M, Christ-Crain M, Russell N (2023). Syndrome of inappropriate antidiuresis: from pathophysiolgy to management. Endocr Rev (online ahead of print). DOI: 10.1210/endrev/bnad010
Russell N, Hoermann R, Cheung AS, Zajac JD, Grossmann M (2022). Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial. Eur J Endocrinol 187 (5):617-627. DOI: 10.1530/EJE-22-0318
Zanker J, Sim M, …, Russell N,..., Daly RM, Scott D (2022). Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. J Cachexia Sarcopenia Muscle (online ahead of print). DOI: 10.1002/jcsm.13115
Russell N, Ghasem-Zadeh A, Hoermann R, Cheung AS, Zajac JD, Shore-Lotenti C, Ebeling PR, Handelsman DJ, Grossmann M (2022). Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial. Eur J Endocrinol 187 (2): 241-256. DOI: 10.1530/EJE-22-0227
Warren AM, Grossmann M, Hoermann R, Zajac JD, Russell N (2022). Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): Design and implementation of an open-label randomised trial. Trials 23 (1): 335. DOI 10.1186/s13063-022-06237-5
Russell N, Allebone J, Dandash O, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Kanaan RA, Grossmann M (2022). Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized trial. Clin Endocrinol (Oxf) (online ahead of print). DOI: 10.1111/cen.14689
Russell N, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Grossmann M (2021). Effects of estradiol on fat mass in men undergoing androgen deprivation therapy: a randomized trial. Eur J Endocrinol 186 (1): 9-23. DOI: 10.1530/EJE-21-0663
Ramchand SK, Russell N, Grossmann M (2021). Optimising bone health during endocrine therapy for hormone sensitive cancer. Endocrinology Today 10 (4). 14-18
Russell N, Grossmann M (2021). Management of bone and metabolic effects of androgen deprivation therapy. Urol Oncol 39 (10): 704-712. DOI: 10.1016/j.urolonc.2018.10.007
Nolan BJ, Brownhill A, Bretherton I, Wong P, Fox S, Locke P, Russell N, Grossmann M, Zajac JD, Cheung A (2020). Relationships between body mass index with oral estradiol dose and serum estradiol concentration in transgender adults undergoing feminising hormone therapy. Ther Adv Endocrinol (11). DOI: 10.1177/2042018820924543
Atallah P, Kanaan R, Russell N, Allebone R, Grossmann M (2020). Cognitive function in prostate cancer patients on androgen deprivation therapy: A case-control study. Gen Hosp Psychiatry 67: 152-153. DOI: 10.1017/j.genhosppsych.2020.04.005
Russell N, Grossmann M (2019). Mechanisms in Endocrinology: Estradiol as a male hormone. Eur J Endocrinol 181 (1): R23-R43. DOI: 10.1530/EJE-18-1000
Russell N, Hoermann R, Cheung A, Ching M, Zajac JD, Handelsman DJ, Grossmann M (2018). Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. Eur J Endocrinol 178 (5): 565-576. DOI: 10.1530/EJE-17-1072
Russell N, Cheung A, Grossmann M (2017). Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocr Relat Cancer 24 (8):R297-R313. DOI: 10.1530/ERC-17-0153
Russell N, O’Brien RC (2016). Diabetes and Hypertension: Is treatment of hyperglycaemia useful? Dialog Cardiovasc Med 21 (2): 136-146
Russell NDF, Cooper ME (2015). 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. Diabetologia 58 (8): 1708-1714. DOI: 10.1007/s00125-015-3600-1
Russell N, Delatycki M, Grossmann M (2015). Metastatic phaeochromocytoma in a 23-year-old woman with an unclassified variant in the von Hippel Lindau disease gene: How can the pathogenicity of this variant be determined? Clin Endocrinol 83 (1): 15-19. DOI: 10.1111/cen.12710
Hanssen NM, Russell N, Cooper ME (2015). Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. Expert Opin Pharmaco 16 (9): 1325-1333. DOI: 10.1517/14656566.2015.1041502
Editorials & letters in refereed journals
Warren AM, Grossmann M, Hoermann R, Lin R, Zajac JD, Russell N (2025): Response to Letter to the Editor from Sumi and Tominaga: “Tolvaptan versus fluid restriction in hospital inpatients with moderate-profound hyponatraemia: An open-label randomised, clinical trial”. J Clin Endocrinol Metab (online ahead of print). DOI: 10.1210/clinem/dgaf538
Wang R, Colman PG, Kyi M, Russell N, Fourlanos S (2021). Longitudinal prevalence of inpatient diabetes mellitus in an Australian hospital across five decades: 1972-2019. Intern Med J 51: 814-815. DOI: 10.1111/imj.15322
Russell N (2019). End-of-life care in hospital. Intern Med J 49 (8): 1056. DOI: 10.1111/imj.14385
Russell N, Grossmann M (2016). Plasma miRNA expression profile in the diagnosis of late-onset hypogonadism. Asian J Androl 18 (5): 713-715. DOI: 10.4103/1008-682X.182819
Russell N, Stevenson AD (2015). Colonoscopy in young women. Intern Med J 45 (11): 1198. DOI: 10.1111/imj.12852
Book chapters
Zajac JD, Seeman E, Russell N, Ramchand SK, Bretherton I, Grossmann M, Davey R (2020). Chapter: Testosterone. Book: Reference Module in Biomedical Sciences. Elsevier. DOI: 10.1016/B978-0-12-801238-3.11263-2
Revised and updated ‘Male Androgen Deficiency’ chapter in Therapeutic Guidelines Sexual and Reproductive Health Version 6. Therapeutic Guidelines 2020
Revised and updated ‘Low Libido in Males’ chapter in Therapeutic Guidelines Sexual and Reproductive Health Version 6. Therapeutic Guidelines 2020
Revised and updated ‘Erectile Dysfunction’ chapter in Therapeutic Guidelines Sexual and Reproductive Health Version 6. Therapeutic Guidelines 2020
Invited conference presentations
Russell N (2025). Syndrome of inappropriate antidiuresis: Management in 2025. RCPA Pathology Update Feb 2025
Russell N (2023). Hormone Dependent Cancers Symposium: Estradiol for men undergoing androgen deprivation therapy for prostate cancer. ESA-SRB Annual Scientific Meeting Nov 2023
Russell N (2021). ESA live webinar: Inpatient hyponatraemia: why it matters and how to manage it in 2021. RACP Congress May 2021
Russell N (2021). Symposium presentation: Estradiol in men with metabolic disorders. 19th International Congress of Endocrinology, ICE Virtual Feb 2021
Russell N (2020). Inpatient hyponatraemia: beyond fluid restriction. Proceedings of the sixty-third annual conference of the Endocrine Society of Australia, ESA Virtual Oct 2020
Russell N (2019). Hyponatraemia - update for general physicians. Proceedings of the annual scientific meeting of the Internal Medicine Society of Australia and New Zealand, Melbourne Australia Sept 2019
Conference abstracts
Russell N (2023). Effects of estradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial. ESA-SRB Annual Scientific Meeting Nov 2023
Russell N, Hoermann R, Ghasem-Zadeh A, Cheung AS, Zajac JD, Handelsman DJ, Grossmann M (2021). Effects of estradiol on bone density and fat mass in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. ESA-SRB-ANZBMS Nov 2021
Russell N, Allebone J, Dhandash O, Hoermann R, Cheung AS, Zajac JD, Handelsman DJ, Kannan RA, Grossmann M (2021). Effects of estradiol on cognition in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. ESA-SRB-ANZBMS Nov 2021
Zanker J, Sim M, …, Russell N, …, Daly R, Scott D (2021). The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force: Findings from the consumer Delphi Process. Australasian Journal on Ageing 40 (1): 55-56
Zanker J, Sim M, …, Russell N, …, Daly R, Scott D (2021). The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force: Findings from the expert Delphi Process. Australasian Journal on Ageing 40 (1): 56-57
Nolan BJ, Brownhill A, …, Russell N, …, Zajac J, Cheung A (2020). Estradiol dose and concentrations in transfeminine individuals. J Endocr Soc 4 (Suppl 1) . Abstract ID: SUN-039. DOI 10.1210/jendso/bvaa046.877.
Wang R, Kyi M, …, Russell N, …, Johnson D, Fourlanos S (2019). Diabetes and acute impaired glycaemia affects two thirds of inpatients: point-prevalence study in a tertiary hospital. Proceedings of the annual scientific meeting of the Australasian Diabetes Congress, Sydney Australia Aug 2019
Russell N, Delatycki M, Grossmann M (2014). Case report: a 23-year-old woman with malignant phaeochromocytoma. Proceedings of the Endocrine Society of Australia Clinical Weekend, Torquay Australia Aug 2014
Russell N, Varadarajan S (2013). A young man with refractory acromegaly. Proceedings of the fifty-sixth annual conference of the Endocrine Society of Australia, Sydney Australia Aug 2013
Russell N, Russell D, Nanayakkara N, Seymour C, Colman PG, Fourlanos S (2012). Doubling of diabetes prevalence in hospital inpatients from 1996-2012. Proceedings of the annual scientific meeting of the Australian Diabetes Society and Australian Diabetes Educators Association, Gold Coast Australia Aug 2012
Non-refereed articles
Russell N, Grossmann M (2016). Not a benign condition (Hyponatraemia therapy update part 2). Australian Doctor 5 August 2016: 31-35.
Russell N, Grossmann M (2016). Water balance (Hyponatraemia therapy update part 1). Australian Doctor 29 July 2016: 31-34.
Russell N, Cooper ME (2015). Type 2 diabetes management in Australia: where are we and where are we headed? Diabetes Management Journal 2: 4-5.